Related Experiment Video
Updated: Jun 8, 2026
13:36
Scalable Fluidic Injector Arrays for Viral Targeting of Intact 3-D Brain Circuits
Published on: January 21, 2010
14.3K
The MED13L Foundation strategic research plan: a roadmap to the future
Rachel Heilmann1, Anna Pfalzer2,3, Terry Jo Bichell2
1The MED13L Foundation, PO Box 283, Barrington, NJ 08007, USA COMBINEDBrain, Brentwood, TN, USA.
Therapeutic Advances in Rare Disease
|December 2, 2024
Summary
A strategic research plan (SRP) guides patient advocacy groups in developing therapies for rare disorders like MED13L syndrome. This plan evaluates current knowledge and preclinical tools to accelerate therapeutic interventions for patients.
Area of Science:
- Rare disease research
- Neurodevelopmental disorders
- Patient advocacy
Background:
- Patient advocacy organizations are crucial for driving therapeutic development in rare disorders.
- The MED13L Foundation, focused on MED13L syndrome, partnered with COMBINEDBrain to create a strategic research plan (SRP).
- This initiative aims to advance clinical trial readiness for rare neurodevelopmental disorders.
Purpose of the Study:
- To create an objective evaluation of MED13L literature, encompassing clinical and basic science knowledge.
- To assess preclinical trial readiness tools essential for developing therapeutic interventions for MED13L syndrome.
- To identify opportunities for expanding knowledge and fostering collaboration within the MED13L research community.
Main Methods:
- A comprehensive review of clinical literature to document symptoms and variant information for individuals with MED13L syndrome.
- Analysis of scientific literature to identify knowledge gaps and research opportunities.
- Interviews with researchers and clinicians to build a collaborative network.
- Evaluation of preclinical trial readiness tools based on FDA guidelines.
- Assessment of the MED13L Foundation's infrastructure and community engagement.
Main Results:
- The SRP provides a consolidated summary of genotype-phenotype information for MED13L syndrome.
- Identified key areas for scientific knowledge expansion in MED13L syndrome research.
- Established a framework for developing therapeutics by assessing preclinical readiness.
- Highlighted strengths and opportunities for the MED13L Foundation to enhance patient-centered research.
Conclusions:
- The MED13L Foundation's SRP serves as a vital resource for prioritizing research and setting organizational goals.
- The plan facilitates collaboration among researchers, clinicians, and the foundation.
- It provides a clear direction towards achieving therapeutic interventions for the MED13L syndrome community.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...